Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001171843-23-004273
Filing Date
2023-06-30
Accepted
2023-06-30 07:33:54
Documents
6
Effectiveness Date
2023-06-30

Document Format Files

Seq Description Document Type Size
1 S-8 s8_063023.htm S-8 49416
2 EXHIBIT 5.1 exh_51.htm EX-5.1 8811
3 EXHIBIT 23.1 exh_231.htm EX-23.1 2059
4 CALCULATION OF FILING FEE exh_107.htm EX-FILING FEES 11835
5 GRAPHIC gdhdr.jpg GRAPHIC 80927
6 GRAPHIC gdlogo.jpg GRAPHIC 5834
  Complete submission text file 0001171843-23-004273.txt   192817
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-273042 | Film No.: 231059440
SIC: 2836 Biological Products, (No Diagnostic Substances)